Home News and Analysis Deals & Exits Adagene locks in $69 mln Series D

Adagene locks in $69 mln Series D

Adagene Inc, an oncology immunotherapy company, has raised $69 million in Series D financing.

Iris Dorbian

22 January 2020

Adagene Inc, an oncology immunotherapy company, has raised $69 million in Series D financing. The lead backer was General Atlantic.

Register now

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Not for publication, email or dissemination